Cynata Therapeutics' Ross Macdonald Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - October 15, 2015) - Stem cell therapies have been slowed by high production costs, batch-to-batch variability and limited seed material. Ross Macdonald, CEO of Cynata Therapeutics Ltd. (ASX: CYP), tells The Life Sciences Report how Cynata Therapeutics' innovative manufacturing methods can generate robust, consistent and inexpensive stem cells, and how this technology is likely to accelerate the commercialization of stem cell therapies worldwide.

The Life Sciences Report: Why does Cynata Therapeutics believe a new way of developing mesenchymal stem cells (MSCs) from induced pluripotent stem cells is needed?

Ross Macdonald: The current methods of manufacturing stem cell-based therapeutic products are likely to constrain their commercialization, largely because of the limitation imposed by the scarcity of stem cells from biologic sources.

Currently, mesenchymal stem cells -- the therapeutic stem cell investigated most vigorously at the moment -- are extracted from primary tissue, including bone marrow, adipose (fat) tissue, placentas or other donor-derived tissues. They're very, very rare. For example, a typical bone marrow aspirate contains around 20 thousand (20K) MSCs, yet one individual dose per patient often contains 150-250 million (150-250M) cells. Expanding cells from 20K to 250M is a huge challenge. If stem cells reproduced themselves faultlessly forever, you could…

Continue reading this interview: Delivering the Triple Whammy that Makes Stem Cell Therapies Commercially Viable: Cynata Therapeutics' Ross Macdonald

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

Cynata Therapeutics Ltd. is a sponsor of Streetwise Reports. Mr. Macdonald had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Macdonald and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.